Stay updated on SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial
Sign up to get notified when there's something new on the SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial page.

Latest updates to the SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page now shows Revision: v3.4.2 instead of v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedThe new screenshot shows an updated revision label: v3.4.1 replaces v3.4.0. No substantive changes to study details, eligibility criteria, outcomes, or navigation were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedAdded a glossary toggle and updated metadata labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0) while removing older labels (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4). These changes do not affect the study content, eligibility, endpoints, or results, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedAn added Revision: v3.3.4 and removal of Revision: v3.3.3 are shown. These are internal version updates and do not modify the study details or user-facing content.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Locations section with Maryland and Texas sites and UT Southwestern Medical Center as sponsor, and updated the revision to v3.3.3. The update also removes the HHS Vulnerability Disclosure link and the prior Maryland, Texas, and UT Southwestern Medical Center entries (v3.3.2).SummaryDifference0.4%

- Check91 days agoChange DetectedA new revision note, v3.3.2, was added and the older v3.2.0 revision was removed. There are no changes to the study content or user-facing information.SummaryDifference0.1%

Stay in the know with updates to SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial page.